Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongsheng Tu

Showing results (31-40 of 200) with videos related to

Pageof 20
Sort By:
Statistical Methods in Medical Research|June 20, 2023
Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributionsYangqing Deng, Dongsheng Tu, Chris J O'Callaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials GroupMichael Crump, Dongsheng Tu, Lois Shepherd, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2005
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials GroupDavid Osoba, Andrea Bezjak, Michael Brundage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossoverHuan Jin, Dongsheng Tu, Naiqing Zhao, et al.
Current Oncology (Toronto, Ont.)|July 25, 2025
Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical TrialChang Yin, Josee-Lyne Ethier, Mark S Carey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trialLorna Butler, Monica Bacon, Mark Carey, et al.
Breast Cancer Research and Treatment|May 4, 2007
Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an exampleJoseph Pater, Dongsheng Tu, Lois Shepherd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention TrialOlivia Meggetto, Elizabeth Maunsell, Rowan Chlebowski, et al.
Frontiers in Genetics|January 1, 2025
Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapyAijun Zhao, Dongsheng Tu, Ye He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials GroupMichael Brundage, David Osoba, Andrea Bezjak, et al.
Pageof 20

Showing results (31-40 of 200) with videos related to

Sort By:
Pageof 20
Statistical Methods in Medical Research|June 20, 2023
Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributionsYangqing Deng, Dongsheng Tu, Chris J O'Callaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials GroupMichael Crump, Dongsheng Tu, Lois Shepherd, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2005
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials GroupDavid Osoba, Andrea Bezjak, Michael Brundage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossoverHuan Jin, Dongsheng Tu, Naiqing Zhao, et al.
Current Oncology (Toronto, Ont.)|July 25, 2025
Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical TrialChang Yin, Josee-Lyne Ethier, Mark S Carey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trialLorna Butler, Monica Bacon, Mark Carey, et al.
Breast Cancer Research and Treatment|May 4, 2007
Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an exampleJoseph Pater, Dongsheng Tu, Lois Shepherd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention TrialOlivia Meggetto, Elizabeth Maunsell, Rowan Chlebowski, et al.
Frontiers in Genetics|January 1, 2025
Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapyAijun Zhao, Dongsheng Tu, Ye He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials GroupMichael Brundage, David Osoba, Andrea Bezjak, et al.
Pageof 20